BC Week In Review | Oct 27, 2017
Clinical News

Replicor HBV combo leads to functional control

Replicor Inc. (Montreal, Quebec) reported interim data from the Moldovan Phase II REP 401 trial to treat non-cirrhotic, hepatitis B e antigen (HBeAg)-negative, chronic HBV infection showing that REP 2139-Mg in combination with Viread tenofovir...
BC Extra | Oct 23, 2017
Clinical News

Replicor HBV combo leads to functional control

Replicor Inc. (Montreal, Quebec) reported interim data from the Moldovan Phase II REP 401 trial to treat chronic HBV infection showing that REP 2139-Mg in combination with Viread tenofovir disoproxil fumarate and Pegasys peginterferon alfa-2a...
BC Week In Review | Feb 3, 2017
Clinical News

REP 2165-Mg: Preliminary Ph II REP 401 data

Preliminary data from 40 treatment-naïve, non-cirrhotic patients with HBeAg-negative chronic HBV infection in the open-label Phase II REP 401 trial showed that once-weekly 250 mg IV REP 2139-Mg and REP 2165-Mg plus Viread tenofovir and...
BC Week In Review | Feb 3, 2017
Clinical News

REP 2139-Mg: Preliminary Ph II REP 401 data

Preliminary data from 40 treatment-naïve, non-cirrhotic patients with HBeAg-negative chronic HBV infection in the open-label Phase II REP 401 trial showed that once-weekly 250 mg IV REP 2139-Mg and REP 2165-Mg plus Viread tenofovir and...
BC Week In Review | Oct 12, 2015
Clinical News

REP 2139-Mg: Phase IIb started

Replicor began the open-label, Moldovan Phase IIb REP 401 trial of REP 2139-Mg or REP 2165-Mg in about 60 Caucasian patients who have received Viread tenofovir disoproxil fumarate for 24 weeks. All patients will continue...
BC Week In Review | Oct 12, 2015
Clinical News

REP 2165-Mg: Phase IIb started

Replicor began the open-label, Moldovan Phase IIb REP 401 trial of REP 2139-Mg or REP 2165-Mg in about 60 Caucasian patients who have received Viread tenofovir disoproxil fumarate for 24 weeks. All patients will continue...
Items per page:
1 - 6 of 6